The Clorox Company

The filings provided give a narrow view of Clorox. The 10-Q excerpt covers controls, a share repurchase table, trading-plan disclosure, and an exhibit index, but it has no discussion of segment results, product performance, or margins, and no risk-factor text, which the filing incorporates by reference from the fiscal 2025 Form 10-K. Readers may want to look at that 10-K directly for the risk disclosures this excerpt omits. On the annual revenue series, the numbers are steady rather than growing. Fiscal 2025 revenue of $7.1 billion was roughly 0.1% above fiscal 2024's $7.09 billion, and fiscal 2024 was about 4.1% below fiscal 2023's $7.39 billion. The capital-return picture is specific. The 2018 Open-Market Program authorized up to $2,000 million, and $876 million remained available at the end of each month of the third quarter, with no shares bought in January, February, or March 2026. The Evergreen Program, used to offset dilution from stock compensation, has no dollar limit and is not counted in that remaining figure. The two March 6, 2026 credit agreements were filed with a March 10, 2026 Form 8-K. The excerpt does not state their size or terms, so this analysis cannot assess them. Forensic scores: none are on file for Clorox in this dataset, so no Beneish M-Score, Piotroski F-Score, Altman Z-Score, or Fog Index is cited here. A Beneish score screens reported numbers for patterns sometimes associated with manipulation, a Piotroski score counts financial-health checks, an Altman Z-Score estimates financial distress risk, and a Fog Index measures how hard text is to read. None of these can be read for this company from the material provided.

Catalyst.The excerpt provided is mainly the 10-Q's controls, share repurchase, trading-plan, and exhibit sections, so it contains no management discussion of results drivers. The most concrete activity described is the phased technology transformation: the transition of core U.S. operations to a new enterprise resource planning system began in the first fiscal quarter of 2026 and was completed in the third quarter. On annual figures, revenue was $7.1 billion for fiscal 2025 against $7.09 billion for fiscal 2024, roughly flat, after $7.39 billion in fiscal 2023. On March 6, 2026, the company entered a 364-day revolving credit agreement and a term credit agreement.

Hidden risk.The tension a casual reader could miss sits between the ERP cutover and the internal control language. Management concluded disclosure controls were effective, but the filing also says it changed internal control over financial reporting to address processes affected by the ERP implementation, which was completed in the third quarter of fiscal 2026. The filing does not report a control weakness, but a system migration across core U.S. operations is the kind of change readers may want to look at closely in later filings. Separately, the company bought no shares in the third quarter, with $876 million still available under the 2018 Open-Market Program. The risk-factor text is not in the provided data, so this paragraph cannot assess those disclosures.